Table 3 |
||||||||
|
Association between Anti-Ro52/TRIM21 antibodies and disease severity (range, 0 to 4) |
||||||||
|
Whole group (N = 963) |
Anti-Ro52/TRIM21 antibody positive (n = 194) |
Anti-Ro52/TRIM21 antibody negative (n = 769) |
Odds ratio (95% CI) and P values (Anti-Ro52/TRIM21 positive vs negative) |
|||||
|
|
||||||||
|
Mean |
SD |
Mean |
SD |
Mean |
SD |
|||
|
|
||||||||
|
General |
0.89 |
1.22 |
1.16 |
1.41 |
0.82 |
1.16 |
1.23 (1.09, 1.39) |
0.0061 |
|
Skin |
1.25 |
0.68 |
1.23 |
0.60 |
1.25 |
0.69 |
NS |
|
|
Kidney |
0.12 |
0.61 |
0.12 |
0.61 |
0.12 |
0.61 |
NS |
|
|
Peripheral vascular |
1.54 |
1.25 |
1.58 |
1.26 |
1.53 |
1.24 |
NS |
|
|
Joint/tendon |
0.73 |
1.19 |
0.73 |
1.22 |
0.73 |
1.18 |
NS |
|
|
Muscle |
0.25 |
0.74 |
0.33 |
0.89 |
0.22 |
0.70 |
NS |
|
|
Gastrointestinal |
1.95 |
0.82 |
2.01 |
0.78 |
1.93 |
0.82 |
NS |
|
|
Lung |
1.38 |
1.11 |
1.56 |
1.08 |
1.34 |
1.12 |
1.19 (1.04, 1.37) |
0.0084 |
|
Heart |
0.50 |
1.00 |
0.60 |
1.12 |
0.48 |
0.97 |
NS |
|
|
Physician global assessments of severity (range, 0-10) |
2.77 |
2.26 |
2.99 |
2.31 |
2.71 |
2.24 |
NS |
|
|
Patient global assessments of severity (range, 0-10) |
3.64 |
2.61 |
3.66 |
2.67 |
3.63 |
2.60 |
NS |
|
|
|
||||||||
|
CI, confidence interval; NS, not significant; SD, standard deviation. |
||||||||
|
Hudson et al. Arthritis Research & Therapy 2012 14:R50 doi:10.1186/ar3763 |
||||||||
